Name: Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Generic, brand name and therapeutic class of product
Published: 2026-09-17T18:16:06-04:00

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

4 evidence topics · 4 sources

Established name, proprietary name, and development code

“DURAVYU™ (vorolanib intravitreal insert a/k/a EYP-1901)” (opens the source at this quote in a new tab)

Therapeutic class and delivery technology

“Our lead product candidate, DURAVYU™ (a/k/a EYP-1901), is an investigational sustained delivery treatment for vascular endothelial growth factor (VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI) with Durasert E™.” (opens the source at this quote in a new tab)

“A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD” (opens the source at this quote in a new tab)

Manufacturer: EyePoint

“EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases.” (opens the source at this quote in a new tab)
“The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases” (opens the source at this quote in a new tab)

Sponsor and licensor of vorolanib

“Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.” (opens the source at this quote in a new tab)